v3.26.3
Consolidated Statements of Profit or Loss and Other Comprehensive Income
 12 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2024
USD ($)
$ / shares
Profit or Loss [Abstract]      
Revenue from contracts with customers $ 2,767,888 $ 3,633,422 $ 299,228
Cost of sales (2,504,499) (3,594,146)
Gross Profit 263,389 39,276 299,228
Other income 10,734,382 10,256,740 1,343,062
Other losses (868,162) (351,646) (1,226,108)
General and administrative expenses (16,215,702) (14,638,013) (13,039,246)
Research and development expenses (49,962,899) (27,515,194) (23,086,267)
Share-based payments expenses (2,405,955) (1,895,348) (2,640,178)
Gain/(loss) on movement in contingent consideration 1,671,289 (4,069,680) (8,860,358)
Operating loss (56,783,658) (38,173,865) (47,209,867)
Finance expenses (112,396) (65,300) (642,888)
Loss before income tax (56,896,054) (38,239,165) (47,852,755)
Income tax expense (54,440) (103,292) (96,364)
Loss for the year (56,950,494) (38,342,457) (47,949,119)
Other comprehensive income/(loss)      
Exchange differences on translation of foreign operations 621,440 464,034 202,956
Total comprehensive loss for the year (56,329,054) (37,878,423) (47,746,163)
Total comprehensive loss for the year is attributable to:      
Owners of Radiopharm Theranostics Limited (54,527,710) (36,239,055) (45,781,950)
Non-controlling interests (1,801,344) (1,639,368) (1,964,213)
Total comprehensive loss for the year $ (56,329,054) $ (37,878,423) $ (47,746,163)
Loss per share for loss attributable to the ordinary equity holders of the group:      
Basic loss per share (in Dollars per share) | $ / shares $ (1.79) $ (1.76) $ (12.41)
Diluted loss per share (in Dollars per share) | $ / shares $ (1.79) $ (1.76) $ (12.41)